Description

Jazz Composition
active ingredients: ethinylestradiol, drospirenone, calcium levomefolate;

1 package contains 28 tablets (24 pink and 4 light orange tablets);

1 pink tablet contains ethinylestradiol 0.02 mg (in the form of a clathrate with betadex) and drospirenone 3 mg, calcium levomefolate 0.451 mg;

Jazz excipients: lactose monohydrate, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, magnesium stearate, hypromellose, macrogol 6000, talc, titanium dioxide (E 171), iron oxide red (E 172);

1 tablet of light orange color contains 0.451 mg of calcium levomefolate;

excipients: lactose monohydrate, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, magnesium stearate, hypromellose, macrogol 6000, talc, titanium dioxide (E 171), iron oxide yellow (E 172), iron oxide red (E 172).

Jazz Dosage form
Film-coated tablets.

Basic physical and chemical properties:

film-coated tablets containing hormones, round, biconvex, pink, on one side of which “Z +” is displaced in a regular hexagon;
film-coated tablets containing only levomefolate, round, biconvex, light orange in color, on one side of which “M +” is displaced in a regular hexagon.

Pharmacological group
Hormonal contraceptives for systemic use.

ATX code G03A A12.

Pharmacological properties

Pharmacodynamics.

Mechanism of action

Combined oral contraceptives (COCs) reduce the risk of pregnancy mainly by inhibiting ovulation. Other possible mechanisms include changes in the nature of cervical mucus, which make it difficult for sperm to enter, and changes in the endometrium, which reduce the likelihood of implantation.

Pharmacodynamic properties

Drospirenone is an analogue of spironolactone, which has antimineralocorticoid and antiandrogenic properties. The estrogenic component of Jazz Plus is ethinyl estradiol.

Contraceptive action

Special studies of the pharmacodynamic properties of the drug Jazz Plus were not carried out.

Two studies evaluated the effect of the 3 mg drospirenone / 0.02 mg ethinylestradiol combination on the suppression of ovarian activity, determined by follicular size using transvaginal ultrasound and analysis of serum hormones (progesterone and estradiol) during two treatment cycles (21-day period of taking active pills plus a 7-day interval for taking pills). Suppression of ovulation was observed in more than 90% of the subjects participating in the study. One study compared the suppression of ovarian activity with a combination of 3 mg drospirenone / 0.02 mg ethinylestradiol in two different regimens (24-day active tablet intake plus 4-day interval and 21-day active tablet intake plus 7-day dose). interval in admission) for two cycles of treatment. During the first treatment cycle, ovulation was not observed in any of the women (0 / 49.0%) who received the drug in the 24-day regimen, and was observed in one woman (1 / 50.2%), who took the drug in 21 – daytime mode. After deliberate non-compliance with the dosage (three missed active tablets during the first three days of the cycle) during the second cycle of treatment, ovulation was observed in 1 patient (1 / 49.2%) from the group where the 24-day regimen was used, and in 4 patients (4 / 50.8%) from the group of drug use in the 21-day regimen.